Patients with tumours expressing high amounts of the EGFR had an improved response to treatment with erlotinib (Shepherd et al, 2005) and the presence of specific mutations around the ATP binding domain of the receptor was found to increase the response to gefitinib treatment (Lynch et al, 2004; Paez et al, 2004). The gene discussed is EGFR; the disease is neoplasm.